CA3104860A1 - Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile - Google Patents

Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Download PDF

Info

Publication number
CA3104860A1
CA3104860A1 CA3104860A CA3104860A CA3104860A1 CA 3104860 A1 CA3104860 A1 CA 3104860A1 CA 3104860 A CA3104860 A CA 3104860A CA 3104860 A CA3104860 A CA 3104860A CA 3104860 A1 CA3104860 A1 CA 3104860A1
Authority
CA
Canada
Prior art keywords
diffraction pattern
ray powder
powder diffraction
morphic form
crystalline salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104860A
Other languages
English (en)
French (fr)
Inventor
Mahmoud Mirmehrabi
Marco Jonas
Pavan Karthik BATCHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of CA3104860A1 publication Critical patent/CA3104860A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3104860A 2018-07-02 2019-07-02 Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile Pending CA3104860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692914P 2018-07-02 2018-07-02
US62/692,914 2018-07-02
PCT/US2019/040276 WO2020010068A1 (en) 2018-07-02 2019-07-02 Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

Publications (1)

Publication Number Publication Date
CA3104860A1 true CA3104860A1 (en) 2020-01-09

Family

ID=67441642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104860A Pending CA3104860A1 (en) 2018-07-02 2019-07-02 Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

Country Status (12)

Country Link
US (3) US20210122740A1 (https=)
EP (2) EP3818057A1 (https=)
JP (2) JP2021530456A (https=)
KR (2) KR102890565B1 (https=)
CN (1) CN112638904A (https=)
AR (1) AR115666A1 (https=)
AU (2) AU2019298236A1 (https=)
CA (1) CA3104860A1 (https=)
IL (2) IL321116A (https=)
MX (3) MX2021000107A (https=)
TW (1) TW202019914A (https=)
WO (1) WO2020010068A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4406594T (lt) 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
US12595254B2 (en) 2020-09-10 2026-04-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Resmetirom, preparation method therefor, and use thereof
WO2022086894A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
WO2022225827A1 (en) * 2021-04-21 2022-10-27 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
JP2024544538A (ja) * 2021-11-11 2024-12-03 ターンズ・ファーマシューティカルズ・インコーポレイテッド ＴＨＲ－βアゴニストによる肝障害の治療
WO2024263714A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025172958A1 (en) * 2024-02-16 2025-08-21 Metrochem Api Pvt Ltd Solid state forms of resmetirom
WO2025231587A1 (zh) * 2024-05-06 2025-11-13 杭州科巢生物科技有限公司 一种瑞司美替罗无水晶型ch及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
PL1919878T3 (pl) * 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
LT4406594T (lt) * 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) * 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist

Also Published As

Publication number Publication date
US20250074898A1 (en) 2025-03-06
AU2025200189A1 (en) 2025-01-30
IL279700A (en) 2021-03-01
TW202019914A (zh) 2020-06-01
JP2024105460A (ja) 2024-08-06
WO2020010068A1 (en) 2020-01-09
MX2021000107A (es) 2021-05-27
CN112638904A (zh) 2021-04-09
JP2021530456A (ja) 2021-11-11
EP3818057A1 (en) 2021-05-12
EP4552643A3 (en) 2025-07-02
MX2023009701A (es) 2023-08-29
US20250368626A1 (en) 2025-12-04
AU2019298236A1 (en) 2021-01-21
KR102890565B1 (ko) 2025-11-24
IL321116A (en) 2025-07-01
US20210122740A1 (en) 2021-04-29
KR20250167140A (ko) 2025-11-28
KR20210027454A (ko) 2021-03-10
AR115666A1 (es) 2021-02-10
EP4552643A2 (en) 2025-05-14
MX2024013198A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20250074898A1 (en) Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
JP5770928B2 (ja) Ｎ‐［２‐（７‐メトキシ‐１‐ナフチル）エチル］アセトアミドの医薬的に許容される共結晶及びそれらの調製方法
JP2023104925A (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
JP7153030B2 (ja) オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
CN116249695A (zh) 结晶PPAR-δ激动剂
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
JP2024546844A (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
US8946474B2 (en) Polymorphic form of a calcimimetic compound
AU2025200217A1 (en) Systems and methods for preparing tailored radioactive isotope solutions
CA3034535C (en) Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
EP3941588A1 (en) Co-crystal forms of selinexor
US9056814B2 (en) Polymorphic form of a calcimimetic compound
WO2019011316A1 (zh) 一种btk激酶抑制剂的结晶形式及制备方法
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
CN114401711A (zh) 1,2,4-噁二唑衍生物的固体制剂
CA3125694A1 (en) Crystalline solvate of binimitinib with dmso and cocrystalline form of binimitinib with citric acid

Legal Events

Date Code Title Description
D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250411

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260114

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260114